Futibatinib

ATC Code L01EN04

Futibatinib

Definition

An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Futibatinib selectively and irreversibly binds to and inhibits FGFR, which may result in the inhibition of both the FGFR-mediated signal transduction pathway and tumor cell proliferation, and increased cell death in FGFR-overexpressing tumor cells. FGFR is a receptor tyrosine kinase essential to tumor cell proliferation, differentiation and survival and its expression is upregulated in many tumor cell types.

Also known as 2-Propen-1-one, 1-((3S)-3-(4-Amino-3-(2-(3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-1-pyrrolidinyl)-, FUTIBATINIB, Lytgobi, TAS 120, TAS-120, TAS120 — per NCIT

Also identified as

Indications

Disease Relation Source
Cholangiocarcinoma may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Alimentary part of gastrointestinal system may treat a disease of this organ DERIVED · CC BY 4.0
Bile ducts may treat a disease of this organ DERIVED · CC BY 4.0
Biliary system may treat a disease of this organ DERIVED · CC BY 4.0

3 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.